Determination of model appropriateness

Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Modeling Perspective

Volumn , Issue , 2002, Pages 73-104

  Williams, Paul J ^a   Ette, Ene I ^b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35248817071     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. EI Ette, R Miller, WR Gillespie, et al. The population approach: FDA experience. In: L Aarons, LP Balant, G Danhof, et al., eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commision of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1996, pp 272-275.
2. Guidance for Industry: Population Pharmacokinetics. U.S. Department of Health and Human Services, Food and Drug Administration. February 1999.
3. EI Ette, T Ludden. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 12(12):1845-1855, 1995.
4. J Mandema, D Verotta, LB Sheiner. Building population pharmacokinetic-pharmacodynamic models. In: DZ D’Argenio, ed. Advanced Pharmacokinetic and Pharmacodynamic Systems Analysis. New York: Plenum Press, 1995, pp 69-86.
5. EI Ette. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495, 1997.
6. GEP Box. Robustness in the strategy of scientific model building. In: RL Laurer, GN Wilkinson, eds. Robustness in Statistics. New York: Academic Press, 1979, pp 201-236.
7. F Mentre, ME Ebelen. Validation of population pharmacokinetic-pharmacocynamic analyses: review of proposed approaches. In: LP Balant and L Aarons, eds. The Population Approach: Measuring and Managing Variability in Response Concentration and Dose (COST B1). Brussels: Office for Official Publications of the European Communities, 1997, pp 146-160.
8. NHG Holford, M Hale, HC Ko, JL Steimer, LB Sheiner, CC Peck. Simulation in drug development: good practices. Washington, DC: Center for Drug Development Science, Georgetown University, 1999.
9. EI Ette, H Sun, TM Ludden. Balanced designs in longitudinal population pharmacokinetic studies. J Clin Pharmacol 38:417-423, 1998.
10. MF Delgado Iribarnegaray, B Santo, MJ Garcia Sanchez, MJ Otero, AC Falcao, A Dominguez-Gil. Carbamazepine population pharmacokinetics in children: mixed-effect models. Ther Drug Monit 19:132-139, 1997.
11. RP Hirsch. Validation samples. Biometrics 47:1193-1194, 1991.
12. EB Roecker. Prediction error and its estimation for subset-selected models. Technometrics 33:459-468, 1991.
13. H Sun, EO Fadiran, CD Jones, L Lesko, SM Huang, K Higgins, C Hu, S Machado, S Maldonado, R Williams, M Hossain, EI Ette. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 37:41-58, 1999.
14. B Efron. Estimating the error rate of a prediction rule: improvement on cross-validation. J Am Stat Assoc 78:461-470, 1983.
15. B Efron. Bootstrap methods: another look at the jackknife. Ann Stat 7:1-26, 1979.
16. B Efron, G Gong. A leisurely look at the bootstrap, the jackknife and cross-validation. American Statistician 37:36-48, 1983.
17. CA Hunt, G Givens, S Guzy. Bootstrapping for pharmacokinetic models: Visualization of predictive and parameter uncertainty. Pharmaceutical Research 15:690-697, 1998.
18. EI Ette. Comparing non-hierarchical models: Application to non-linear mixed effects modeling. Comput Biol Med 26:505-512, 1996.
19. A Gelman, XL Meng, H Stern. Posterior predictive assessment of model fitness via realized discrepancies. Statistica Sinica 6:733-807, 1996.
20. SB Duffull, S Chabaud, P Nony, L Chritian, P Girard, L Aarons. A pharmacokinetic simulation model for ivabradine in healthy volunteers. Eur J Phamaceut Sci 10:285-294, 2000.
21. SB Duffull, L Aarons. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. Eur J Phar-maceut Sci 10:275-284, 2000.
22. JF Bennet, JC Wakefield, LF Lacey. Modeling of trough plasma bismuth concentrations. J Pharmacokinet Biopharm 25:79-106, 1997.
23. EH Cox, C Veyrat-Follet, S Beal, S Fuseau, S Kenkare, LB Sheiner. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the anti-emetic effect of ondansetron. J Pharmacokinet Biopharm 27:625-644, 1999.
24. LE Friberg, A Freijs, M Sandstrom, M Karlsson. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 295:734-740, 2000.
25. H Yano, SL Beal, LB Sheiner. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinetic Pharmacodynam 28:171-191, 2001.
26. PJ Williams, JR Lane, EC Capparelli, YH Kim, RB Coleman. Direct comparison of three methods for predicting digoxin concentrations. Pharmacotherapy 16:1085-1092, 1996.
27. LB Sheiner, SL Beal. Some suggestions for measuring predictive performance. J Pharmacokinetic Biopharm 9:503-511, 1991.
28. L Aarons, S Vozeh, M Wenk, M Weiss, PH Weiss, F Follath. Population pharmacokinetics of tobramycin. Br J Clin Pharmacol 28:305-314, 1989.
29. R Bruno, N Vivier, JC Vergniol, SL De Phillips, G Montay, LB Sheiner. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24:153-172, 1996.
30. JP Utz, BS Tynes, HJ Shadom, RJ Duma, MM Kannan, KN Mason. 5-Flourocyto-sine in human cryptococcosis. Antimicrob Agents Chemother 344-346, 1968.
31. JP Utz: Flucytosine. N Eng J Med 286:777-778, 1972.
32. CO Record, JM Skinner, P Sleight, DCE Speller. Candida endocarditis treated with 5-fluorocytosine. Brit Med J 1(5743):262-264, 1971.
33. R Schlegel, GM Bernier, JA Bellanti, DA Maybee, GB Osborne, JL Stewart, et. al. Severe candidiasis associated with thymic dysplasia, IgA deficiency and plasma antilymphocyte effects. Pediatrics 45:926-936, 1970.
34. JP Sanford, DN Gilbert, MA Sande. The Sanford Guide to Antimicrobial Therapy, 1995, p 112.
35. DN Wade, G. Sudlow. The kinetics of 5 Fluorocytosine elimination in man. Aust NZ J Med 2:153-158, 1972.
36. TH Ittel, UF Legler, A Polak, WM Glockner, HG Sierberth. 5 Fluorocytosine kinetics in patients with acute renal failure undergoing continuous hemofiltration. Chemotherapy 33:77-84, 1987.
37. EI Ette, P Williams, H Sun, E Fardiran, F Ajayi, LC Onyiah. The process of knowledge discovery from large pharmacokinetic data sets. J Clin Pharmacol 41:25-34, 2001.
38. YH Kim, PJ Williams, JR Lane, EV Capparelli, MJ Liu. 5 Flourocytosine: population pharmacokinetic model development, nonparametric bootstrap validation and dosing strategy evaluation [abstract 2008]. Quest for the magic bullet: an astounding century, Nov 14—18, 1999, New Orleans, LA. AAPS Pharma Sci Supplement 1:S4, 1999.
39. BJ Devine. Gentamicin therapy. Drug Intell Clin Pharm 8:650-655, 1974.
40. D Cockcroft, M Gault. Creatinine clearance from serum creatinine. Nephron 16:41, 1976.
41. J Schonebeck, A Polak, M Fernex, HJ Scholer. Pharmacokinetic studies on the oral antimycotic agent 5 fluorocytosine individuals with normal and impaired renal function. Chemotherapy 18:321-336, 1973.
42. EK Franke, WA Ritschel. Quick estimation of the absorption rate constant for clinical purposes. Drug Intell Clin Pharm 10:77-82, 1976.
43. Bryan FJ Manly. Randomization, Bootstrap and Monte Carlo Methods in Biology. 2nd ed. London: Chapman and Hall, 1998, pp 34-68.
44. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman and Hall, 1993.